U.S. Oil and Gas Stock News

While Golden Entertainment, Inc. ( NASDAQ:GDEN ) might not have the largest market cap around , it received a lot of...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...

Quest Resource Holding Corporation ( NASDAQ:QRHC ) shareholders would be excited to see that the share price has had a...

Investors who take an interest in Energizer Holdings, Inc. ( NYSE:ENR ) should definitely note that the Independent...

Even if it's not a huge purchase, we think it was good to see that Jeremy Jameson, the EVP & Chief Credit Officer of...

It hasn't been the best quarter for World Acceptance Corporation ( NASDAQ:WRLD ) shareholders, since the share price...

Lincoln Educational Services Corporation ( NASDAQ:LINC ) shareholders would be excited to see that the share price has...

What Is Moving Leggett & Platt Stock Right Now Leggett & Platt (LEG) has quietly climbed about 27% over the past month, even as its one year return is still slightly negative. This setup has bargain hunters wondering if this rebound has more room to run. See our latest analysis for Leggett & Platt. At a share price of $11.17, Leggett & Platt has seen momentum improve recently, with a 30 day share price return of roughly 27%. However, the 3 year total shareholder return remains deeply...

Molina Healthcare (MOH) is under heavy pressure, with multiple securities class actions accusing management of downplaying medical cost trends just as the company cut its 2025 earnings outlook and warned on Medicaid headwinds. See our latest analysis for Molina Healthcare. Those legal and earnings setbacks have come after a sharp rerating, with the share price at $151.86 and a year to date share price return of negative 47.13 percent. The three year total shareholder return of negative 55.49...

Coca-Cola (KO) has quietly climbed about 15% over the past year, even after a mild pullback this week, and that kind of steady, low drama performance always gets income focused investors paying attention. See our latest analysis for Coca-Cola. That recent 7 day share price pullback sits against a much sturdier backdrop, with a year to date share price return of 13.2% and a 1 year total shareholder return of 15.3%, suggesting momentum is still gently building rather than fading. If Coca-Cola’s...

If you are wondering whether Prologis at around $127.98 is still a smart way to play the logistics real estate boom, or if most of the upside is already priced in, you are in the right place. Despite a modest dip of around 0.4% over the last week, the stock is up 3.4% over 30 days, 22.8% year to date, and 18.4% over the past year, with a 50.9% gain over five years that signals long term strength. Recent sentiment has been shaped by ongoing demand for modern logistics facilities, as e...

APA Corporation ( NASDAQ:APA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...

The latest move in Alvotech (NasdaqGM:ALVO) is being driven by a major regulatory win: European Commission approval of its denosumab biosimilar AVT03, opening the door to a sizeable osteoporosis and oncology market. See our latest analysis for Alvotech. The AVT03 approval has clearly sparked a rebound in sentiment, with a 1 day share price return of 7.89 percent and 30 day share price return of 12.09 percent. However, the 1 year total shareholder return of negative 52.06 percent shows...

Lamb Weston Holdings (LW) has quietly drifted lower this year, even as its earnings and revenue continue to grow. With the stock down about 10% year to date, investors are revisiting its long term case. See our latest analysis for Lamb Weston Holdings. At around a 10% year to date share price decline and a 1 year total shareholder return of roughly negative 21 percent, the stock looks more like a slow bleed than a collapse. Recent setbacks appear to reflect investors reassessing execution...

Victoria's Secret (VSCO) kicked off its latest earnings update with Q2 2026 revenue of about $1.5 billion and basic EPS of $0.20, supported by net income of $16 million and a 4% same store sales uptick that marks a cleaner read on underlying demand. The company has seen quarterly revenue move from $1.35 billion in Q1 2025 to $1.46 billion in Q2 2026, while EPS has swung from a loss of $0.71 in Q3 2025 to the current $0.20. This sets the stage for investors to focus on whether recent margin...

APA (APA) has quietly climbed about 25% over the past month and roughly 19% in the past 3 months, drawing fresh attention to whether the stock still offers value at current levels. See our latest analysis for APA. Zooming out, APA’s recent 1 month share price return of around 25% builds on a solid year to date share price gain, even as the 3 year total shareholder return remains negative. This suggests sentiment has only recently swung back in its favor. If APA’s rebound has you rethinking...

While Akso Health Group ( NASDAQ:AHG ) shareholders are probably generally happy, the stock hasn't had particularly...

If you are wondering whether Par Pacific Holdings is still worth buying after its big run, you are not alone. This article is going to unpack what the current price really implies. The stock has cooled slightly over the last week, down 4.3%, but it is still up 16.1% over 30 days, 161.8% year to date, and 171.9% over the past year. This naturally raises questions about how much upside is left versus how much risk has been priced in. Recent moves have been driven by a mix of refining margin...

Multiple Wall Street firms have recently reiterated or launched Buy ratings on Coterra Energy (CTRA), signaling growing confidence in its multi basin strategy and positioning within a still volatile energy tape. See our latest analysis for Coterra Energy. That upbeat backdrop helps explain why, at a latest share price of $27.39, Coterra has logged a solid 90 day share price return of 14.22 percent and a 1 year total shareholder return of 13.73 percent. This suggests that momentum in the story...

DocuSign (DOCU) just posted Q3 2026 results with revenue of $818.4 million and basic EPS of $0.41, as the company continues to turn its profitability track record from headline to habit. Over the past few quarters, revenue has stepped up from $754.8 million in Q3 2025 to $776.3 million in Q4 2025, then to $763.7 million and $800.6 million in Q1 and Q2 2026, while EPS moved from $0.31 in Q3 2025 to a trailing twelve month figure of $1.49. With that backdrop, investors are watching how much of...

In late November and early December 2025, Kymera Therapeutics highlighted progress for KT-621, its first-in-class oral STAT6 degrader, including completion of the BroADen Phase 1b atopic dermatitis trial and initiation of the BROADEN2 Phase 2b study, while scheduling Phase 1b data release for December 8, 2025. This latest update positions KT-621 at the center of Kymera’s effort to move beyond early proof-of-mechanism and potentially build a multi-indication Type 2 inflammation franchise...

With a median price-to-earnings (or "P/E") ratio of close to 19x in the United States, you could be forgiven for...

At the Barclays Financial Services Conference in September, MarketAxess CEO Chris Concannon and CFO Ilene Fiszel Bieler outlined the company’s evolving growth plan, emphasizing progress in non‑US credit revenue, stronger algorithmic and block trading activity, and plans to deepen integration with ICE Bonds while prioritizing organic growth and selective share repurchases. An interesting takeaway is management’s emphasis on emerging markets, where electronic bond trading remains minimal,...

In recent months, BioMarin Pharmaceutical reported very large year-over-year EPS growth in Q2 2025, highlighted the margin benefits of its 2024 restructuring, and raised guidance for revenue, income, and operating margins while pointing to limited competition for its orphan drug portfolio. Management now expects the full impact of these cost and efficiency measures to emerge in 2026, with promising late-stage trials potentially adding to an already focused rare-disease franchise. Next, we’ll...